Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Memorial Sloan Kettering Cancer Center · Cornell University · +20 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
953
total citations
- FWCI
- 98.23
- Percentile
- 100%
- References
- 29
Citations per year
Authors
18- VAVincent A. Miller
Memorial Sloan Kettering Cancer Center, Cornell University
- VHVera Hirsh
McGill University Health Centre
- JCJacques Cadranel
Sorbonne Université, Hôpital Tenon
- YCYuh-Min Chen
Taipei Medical University, National Yang Ming Chiao Tung University, Taipei Veterans General Hospital
- KPKeunchil Park
Samsung Medical Center
Topics & keywords
Topics
Keywords
- Afatinib
- Medicine
- Erlotinib
- Gefitinib
- Internal medicine
- Clinical endpoint
- Hazard ratio
- Placebo
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.